Abstract
In the last decade, different molecular subtypes of breast cancer have been proposed. Although displaying appreciable association with disease prognosis and the prognostic value of cytotoxic and endocrine therapeutic modalities, the subtypes seem to fail at completely explaining disease behavior and response to treatment. Molecules such as those of the cyclocooxigenase (COX) family, currently composed of three entities (COX 1, 2 and 3) have been shown to be associated with breast carcinogenesis, and the analysis of p53 expression in breast tumors may also offer some additional prognostic clues. Our study is aimed at assessing COX2 and p53 expression in these clinico-pathological surrogate subtypes, and to evaluate whether the expression of these molecules can help further explain the variability in prognosis still found within the clinico-pathological subtypes groups of breast cancer. A total of 183 breast cancer samples were obtained from women treated at the Womeńs Hospital of Campinas State University, Campinas, Brazil, between June 2008 and January 2011. Immunohistochemistry was performed to detect the expression of ER, PR, ki67, COX2, and p53 and the HER2 status of the 183 specimens was assessed using FISH. Two COX2 staini...Continue Reading
References
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Sep 20, 2005·The Breast : Official Journal of the European Society of Mastology·M H ChoK W Min
Feb 13, 2007·The Journal of Surgical Research·Marnix A de RoosJelle Wesseling
Nov 7, 2009·Journal of the National Cancer Institute·Sacha J HowellAnne C Armstrong
Nov 3, 2010·Journal of Oncology Practice·M Elizabeth H HammondSarah Temin
Feb 10, 2011·The Oncologist·Charles M Perou
May 3, 2011·Breast Cancer Research and Treatment·Hee Sung KimDong-Young Noh
Mar 27, 2012·The Journal of Pharmacology and Experimental Therapeutics·C C WongBasil Rigas
May 3, 2012·Pathology Oncology Research : POR·Beata BiesagaMarek Ziobro
May 24, 2012·Cancer Immunology, Immunotherapy : CII·A C S A HerreraR Cecchini
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aleix PratCharles M Perou
Feb 26, 2013·Human Pathology·Ling ZhouQian Huang
Jun 5, 2013·BMC Cancer·B N Prashanth KumarMahitosh Mandal
Jul 13, 2013·Human Pathology·Ling ZhouQian Huang
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Aug 21, 2013·Cell Biochemistry and Biophysics·Li SunLing Wei
Aug 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C DenkertG von Minckwitz
Oct 15, 2013·Cancer Science·Mitsugu YamamotoHiroko Yamashita
Nov 22, 2013·Oncology Letters·Dhanashri ThoratGopal C Kundu
Jan 15, 2014·Carcinogenesis·Katiuscia DallaglioAdriana Albini
Feb 13, 2014·The American Journal of Pathology·Jaime FornettiPepper Schedin
Mar 19, 2014·Journal of Oncology·Preethi SekarPriyanka Bhatia Soni
May 13, 2014·Medical Oncology·Bar ChikmanJudith Sandbank
Feb 3, 2015·Histopathology·Elisa SpechtAmelie Lupp
Feb 26, 2015·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Amanda Arantes PerezHelenice Gobbi
Citations
Sep 9, 2017·Oncotarget·Bo LiFengtian He
Sep 10, 2020·Cytotechnology·Pei-Yi TanShi-Wei Chai
Oct 4, 2018·Functional & Integrative Genomics·Xing-Bo MoShu-Feng Lei
Dec 11, 2020·NPJ Breast Cancer·Sonali JindalPepper Schedin